asa glp-1 agonist guidelines GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction New therapeutic agents for type
Description
Seino Y, Fukushima M, Yabe D
2023;gfad009
Preclinical combination studies confirm that simultaneous GLP-1R and GIPR activation outperforms either receptor alone for weight reduction and glycemic control
[DOI] [PubMed] [Google Scholar] 87.Terami N., Ogawa D., Tachibana H., Hatanaka T., Wada J., Nakatsuka A., Eguchi J., Horiguchi C.S., Nishii N., Yamada H., et al
El-Yazbi, Perirenal adipose tissue inflammation: novel insights linking metabolic dysfunction to renal diseases
